Virtu Financial LLC Buys Shares of 15,576 Denali Therapeutics Inc. (NASDAQ:DNLI)

Virtu Financial LLC bought a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 15,576 shares of the company’s stock, valued at approximately $334,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC grew its holdings in Denali Therapeutics by 216.7% in the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after buying an additional 1,376 shares during the last quarter. Fisher Asset Management LLC bought a new stake in shares of Denali Therapeutics during the fourth quarter valued at approximately $59,000. Assetmark Inc. increased its position in shares of Denali Therapeutics by 65.3% during the fourth quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock valued at $76,000 after purchasing an additional 1,402 shares during the period. Brandywine Managers LLC bought a new stake in shares of Denali Therapeutics during the fourth quarter valued at approximately $206,000. Finally, Quest Partners LLC bought a new stake in shares of Denali Therapeutics during the fourth quarter valued at approximately $214,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on DNLI shares. UBS Group lowered their price objective on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 9th. Stifel Nicolaus decreased their price target on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday, May 8th. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 price target on shares of Denali Therapeutics in a research note on Wednesday, May 8th. The Goldman Sachs Group decreased their price target on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. Finally, Wedbush decreased their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.22.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $20.62 on Thursday. The firm has a market cap of $2.94 billion, a P/E ratio of -21.48 and a beta of 1.37. The business’s fifty day moving average is $18.75 and its two-hundred day moving average is $19.12. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.11.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 11.46% and a negative net margin of 36.51%. During the same quarter in the prior year, the company earned ($0.80) earnings per share. On average, equities research analysts predict that Denali Therapeutics Inc. will post -2.78 earnings per share for the current year.

Insider Transactions at Denali Therapeutics

In other news, Director Jennifer E. Cook sold 1,458 shares of the business’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $21.73, for a total transaction of $31,682.34. Following the completion of the sale, the director now owns 20,038 shares in the company, valued at $435,425.74. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Steve E. Krognes sold 92,500 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the sale, the director now owns 47,341 shares in the company, valued at $970,490.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jennifer E. Cook sold 1,458 shares of the company’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $21.73, for a total value of $31,682.34. Following the completion of the sale, the director now owns 20,038 shares of the company’s stock, valued at approximately $435,425.74. The disclosure for this sale can be found here. Insiders sold a total of 95,624 shares of company stock worth $1,958,403 over the last 90 days. 7.90% of the stock is owned by insiders.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.